DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Phase 2

Terminated

Conditions: Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Acute Erythroid Leukemia
Myelodysplastic Syndrome With Excess Blasts
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation
Biological: Dilanubicel

First Posted Date: 2019-09-10

Last Posted Date: 2025-01-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04083170

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Cleveland Cord Blood Center, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Phase 1

Suspended

Conditions: Non-Malignant Neoplasm

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Lapine T-Lymphocyte Immune Globulin
Radiation: Total-Body Irradiation
Procedure: Hematopoietic Cell Transplantation
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2019-09-10

Last Posted Date: 2024-12-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04083183

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors

Not Applicable

Terminated

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Behavioral: Health Education
Other: Physical Activity
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-09-09

Last Posted Date: 2023-07-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04081298

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

Not Applicable

Conditions: Colorectal Carcinoma
Lung Carcinoma
Lymphoma
Prostate Carcinoma
Breast Carcinoma

Interventions: Other: Survivorship Care Plan
Other: Questionnaire Administration
Other: Educational Intervention

First Posted Date: 2019-09-09

Last Posted Date: 2025-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 250

Registration Number: NCT04081779

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants

Not Applicable

Completed

Conditions: Healthy Subject

Interventions: Dietary Supplement: Dietary Intervention
Procedure: Dual X-ray Absorptiometry
Other: Questionnaire Administration

First Posted Date: 2019-08-20

Last Posted Date: 2021-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT04062955

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Phase 1

Terminated

Conditions: Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Drug: Nozin
Other: Best Practice

First Posted Date: 2019-08-19

Last Posted Date: 2024-11-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT04060849

Locations: 🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma

Not Applicable

Completed

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Other: Media Intervention
Other: Best Practice
Other: Informational Intervention
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2019-06-14

Last Posted Date: 2022-10-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03986502

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Phase 2

Recruiting

Conditions: Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Interventions: Drug: Thiotepa
Drug: Treosulfan
Drug: Fludarabine Phosphate
Biological: Rabbit Anti-Thymocyte Globulin
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection

First Posted Date: 2019-06-10

Last Posted Date: 2025-03-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03980769

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Radiation: Total-Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Peripheral Blood Stem Cell
Drug: Tacrolimus
Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Drug: Methotrexate
Drug: Cyclosporine
Drug: Busulfan
Drug: Sirolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Biospecimen Collection

First Posted Date: 2019-05-31

Last Posted Date: 2025-02-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03970096

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Glucosamine and Chondroitin in Gut in Preventing People From Inflammation

Phase 1

Completed

Conditions: Healthy Subject

Interventions: Dietary Supplement: Glucosamine Sulfate/Chondroitin Sulfate Tablet
Other: Placebo

First Posted Date: 2019-05-24

Last Posted Date: 2019-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT03963323

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy